GLA and Fabry disease: Given that few studies have evaluated the effect of disease phenotype (classic vs. non-classic) and the extent of baseline renal dysfunction on the long-term rate of progression of renal impairment, we evaluated the impact of urinary proteinuria on eGFR in patients with classic versus non-classic Fabry disease treated with agalsidase alfa using data from FOS.